-
Mashup Score: 0MRD Negativity Status Following Surgery Confers Survival in MIBC - 22 day(s) ago
Patients with muscle-invasive bladder cancer who remain molecular residual disease negative following cystectomy may be spared from adjuvant therapy.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4The Role of Circulating Tumor DNA in Bladder Cancer - 25 day(s) ago
Following a discussion centered on the EV-302 study, Thomas Powles, MBBS, MRCP, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in urothelial cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
A comprehensive discussion on treatment-related adverse events seen in patients receiving enfortumab vedotin and pembrolizumab.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Neoadjuvant pembrolizumab appeared to offer more favorable results among both cisplatin-eligible and cisplatin-ineligible patients.
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 5
The Oncology Brothers are joined by Thomas Powles, MBBS, MRCP, MD, to discuss the role of enfortumab vedotin plus pembrolizumab in the bladder cancer treatment landscape.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
In an interview with Targeted Oncology, Joseph M. Jacob, MD, discussed how bladder preservation is the top reason for refusal of radical cystectomy in the TAR-200 monotherapy cohort of the SunRISe-1 study.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Upfront Surgery May Be Avoidable in Very High-Risk NMIBC Responsive to BCG - Renal and Urology News - 29 day(s) ago
Within 5 years, 22% of patients with very high-risk NMIBC treated with adequate BCG had disease progression
Source: www.renalandurologynews.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2
Neuropathy is an adverse effect that can occur when enfortumab veodtin is administered to patients with locally advanced or metastatic urothelial carcinoma.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Data from the phase 3 EV-302 trial support an application for enfortumab vedotin plus pembrolizumab as a treatment for patients with advanced bladder cancer in China.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0EV-302 Study Design and Results - 1 month(s) ago
Thomas Powles, MBBS, MRCP, MD, joins the Oncology Brothers to discuss the study design and results of the EV-302 trial investigating enfortumab vedotin plus pembrolizumab in untreated advanced urothelial carcinoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Surveillance following cystectomy for patients with muscle-invasive bladder cancer who tested serially negative for MRD with the SignateraTM companion diagnostic experienced positive survival outcomes. #blcsm https://t.co/6Q5FAwGcVy https://t.co/YvK9AbgKXB